Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain.

International Journal of Clinical Practice
Joachim NadstawekKaren Reimer

Abstract

Opioid-induced constipation can have a major negative impact on patients' quality of life. This randomised clinical trial evaluated patient assessment of the efficacy and tolerability of oral prolonged-release (PR) oxycodone when co-administered with oral naloxone PR. Two hundred and two patients with chronic cancer- or non-cancer-related pain undergoing stable oxycodone PR therapy (40, 60 or 80 mg/day) were randomised to one of four intervention groups: 10, 20 or 40 mg/day naloxone PR or placebo. Following a 4-week maintenance phase, patients were followed-up for 2 weeks in which time they received oxycodone PR only. At the end of the maintenance phase, patients and investigators were asked to assess treatment efficacy and tolerability, as well as preference for the titration or maintenance phase. Patient and investigator global assessment of efficacy and tolerability improved with increasing naloxone dose. Efficacy was ranked as 'good' or 'very good' by 50.0%, 67.4% and 72.5% of patients in the 10, 20 and 40 mg naloxone PR dose groups, respectively, compared with 43.5% of patients in the placebo group. Patient assessment of tolerability was similar between treatment groups and placebo, being ranked as 'good' or 'very good' by...Continue Reading

References

Jan 5, 2002·American Journal of Surgery·M Pappagallo
Jan 10, 2002·Journal of Pain and Symptom Management·Maywin Liu, Eric Wittbrodt
Aug 17, 2002·Journal of Pain and Symptom Management·Youn Seon Choi, J Andrew Billings
May 24, 2005·Journal of Pain and Symptom Management·Eija Kalso

❮ Previous
Next ❯

Citations

Jun 6, 2009·Journal of Pain & Palliative Care Pharmacotherapy·Elon Eisenberg
Mar 29, 2013·Expert Opinion on Drug Safety·Mellar DavisPam Gamier
Dec 12, 2012·Expert Opinion on Investigational Drugs·Sebastiano Mercadante, Antonello Giarratano
Jan 5, 2011·Current Medical Research and Opinion·Karsten Ahlbeck
Oct 2, 2009·Peptides·Richard J Bodnar
Apr 7, 2009·Regulatory Peptides·Peter Holzer
Jul 21, 2009·European Journal of Pain : EJP·Andrew Wilcock
Jun 17, 2016·Expert Opinion on Drug Metabolism & Toxicology·Stefano de BiaseGian Luigi Gigli
Oct 5, 2010·Pharmacological Reports : PR·Wojciech Leppert
Mar 31, 2018·Environmental Technology·Ahed ZyoudHikmat S Hilal
Sep 26, 2017·Pain Practice : the Official Journal of World Institute of Pain·Bart J MorlionTony O'Brien
Jun 6, 2018·The Cochrane Database of Systematic Reviews·Bridget CandyPatrick Stone
Aug 23, 2017·The Cochrane Database of Systematic Reviews·Mia Schmidt-HansenJennifer S Hilgart
Jan 10, 2019·Expert Opinion on Pharmacotherapy·Wojciech LeppertJerzy Wordliczek
Jun 15, 2010·Current Opinion in Anaesthesiology·Peter Holzer
Apr 26, 2014·Journal of Physical Therapy Science·Jeonhyeong Lee, Kyochul Seo
May 20, 2017·Clinical Journal of Oncology Nursing·Jeannine M BrantLinda H Eaton
May 15, 2015·The Cochrane Database of Systematic Reviews·Bridget CandyPatrick Stone

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.